See more : Ambrian Plc (AMNZF) Income Statement Analysis – Financial Results
Complete financial analysis of BioVaxys Technology Corp. (BVAXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioVaxys Technology Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sunlight Financial Holdings Inc. (SUNLQ) Income Statement Analysis – Financial Results
- Calbee, Inc. (CLBEY) Income Statement Analysis – Financial Results
- ITHAX Acquisition Corp. (ITHX) Income Statement Analysis – Financial Results
- Shell plc (SHELL.AS) Income Statement Analysis – Financial Results
- TradeUP Acquisition Corp. (UPTDU) Income Statement Analysis – Financial Results
BioVaxys Technology Corp. (BVAXF)
About BioVaxys Technology Corp.
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 133.73K | 962.71K | 726.06K | 238.77K | 0.00 |
| General & Administrative | 2.11M | 2.94M | 4.00M | 775.10K | 229.91K |
| Selling & Marketing | 156.88K | 174.30K | 1.72M | 84.51K | 0.00 |
| SG&A | 2.27M | 3.12M | 5.72M | 859.61K | 229.91K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.40M | 4.08M | 6.44M | 1.10M | 229.91K |
| Cost & Expenses | 2.40M | 4.08M | 6.44M | 1.10M | 229.91K |
| Interest Income | 24.85K | 15.77K | 7.66K | 137.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.40M | 3.80M | 5.98M | 1.01M | 183.34K |
| EBITDA | 0.00 | 3.58M | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.40M | 3.58M | -6.42M | -1.09M | -229.70K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.28M | -7.92M | -478.68K | -93.55K | -33.54K |
| Income Before Tax | -7.69M | -11.73M | -6.46M | -1.10M | -230.12K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 7.64M | 9.93K | 71.69K | 29.66 |
| Net Income | -7.69M | -11.73M | -6.46M | -1.17M | -230.12K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
| EPS Diluted | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
| Weighted Avg Shares Out | 134.15M | 98.18M | 82.93M | 30.05M | 11.02M |
| Weighted Avg Shares Out (Dil) | 134.14M | 98.18M | 82.93M | 28.21M | 10.39M |
BioVaxys Technology to expand cancer vaccine platform with investigator-sponsored trial of colorectal cancer therapy
BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) plans to advance an Investigator-Sponsored Clinical Trial Application(CTA) for BVX-0922, its autologous haptenized tumor vaccine for colorectal cancer (CRC), with the European Medicines Agency (EMEA) this year. An Investigator Sponsored CTA is submitted to regulatory authorities...
BioVaxys announces bioproduction of BVX-1021 for its pan-sarbecovirus vaccine program with Ohio State University
BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) revealed that it has struck an agreement with Millipore-Sigma to manufacture a supply of GLP-grade BVX-1021, its newly developed vaccine for the strain of coronavirus that causes severe acute respiratory syndrome (SARS1), the respiratory illness...
BioVaxys says studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, suggest superior cardiac safety
BioVaxys Technology Corp has revealed that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine candidate, demonstrated that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor. The Vancouver-based biotechnology company said this suggests superior cardiac safety compared...
BioVaxys Technology closes first tranche of C$1M non-brokered private placement
BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) said it has closed the first tranche of its previously announced non-brokered private placement under which it issued 2,680,000 units at a price of $0.15 each for gross proceeds of $402,000. The second tranche of...
BioVaxys Technology set to raise up to C$1M in a non-brokered private placement
BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) announced a non-brokered private placement of up to 6,666,667 company units, at a price of $0.15 per unit, in order to raise gross proceeds of up to about C$1 million. The company said it intends to use the...
BioVaxys tackles cancers and viruses using its robust technology platform
Early clinical-stage biotechnology company developing viral and oncology vaccine platforms Advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology Ramping up for a Phase I study in the EU early next year for its ovarian cancer vaccine Preparing...
BioVaxys announces collaboration with Ohio State University to expand research on reactive pan-sarbecovirus vaccine
BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) announced that it has partnered with Ohio State University to further develop the company's haptenized viral antigen platform to create a broadly reactive pan-sarbecovirus vaccine. The Vancouver-based company said this is its second research collaboration in...
Biovaxys says CoviDTH shows safety and tolerability in pathology and immunology evaluations to support clinical development
BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) revealed that results from its in vivo animal research study support the safety and tolerability of CoviDTH at two intradermal dose levels across a battery of clinical pathology, immunology, and histopathology evaluations. CoviDTH is the...
BioVaxys Technology files international application with Patent Cooperation Treaty for CoviDTH
BioVaxys Technology Corp announced that it has broadened its intellectual property portfolio, after filing an international application for CoviDTH — its T cell diagnostic for detecting an immune response to SARS-CoV-2 — with the Patent Cooperation Treaty (PCT). The Vancouver,...
BioVaxys files application with US Patent and Trademark Office for pan-sarbecovirus vaccine
BioVaxys Technology Corp said it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most sarbecoviruses — the family of...
Source: https://incomestatements.info
Category: Stock Reports